Advice
following an abbreviated submission:
dapagliflozin (Forxiga®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%.
Dapagliflozin offers an additional treatment choice in the therapeutic class of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
SMC has issued separate advice for dapagliflozin in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction (SMC2322).
Download detailed advice639KB (PDF)
Medicine details
- Medicine name:
- dapagliflozin (Forxiga)
- SMC ID:
- SMC2577
- Indication:
For treatment of chronic heart failure
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 August 2023